Conditions

Home / Conditions

 

S-1 and Platinol Combo Shows Promise Against Cervical Cancer, Phase 3 Trial Indicates

S-1 and Platinol Combo Shows Promise Against Cervical Cancer, Phase 3 Trial Indicates

This post was originally published on this site Adding S-1 to Platinol (cisplatin) chemotherapy improved cervical cancer patients’ response to treatment and lengthened the time it took for their disease to progress, according to a Phase 3 clinical trial. Taiho Pharmaceutical, which developed S-1, presented the results at the American Society of Clinical Oncology annual meeting in…

Synthetic Genomics, Advaxis Launch Venture to Produce Synthetic DNA for Immunotherapy Clinical Trials

Synthetic Genomics, Advaxis Launch Venture to Produce Synthetic DNA for Immunotherapy Clinical Trials

This post was originally published on this site Synthetic Genomics and Advaxis have developed a current good manufacturing practice (cGMP) synthetic biology suite to produce synthetic DNA constructs. The cGMP facility meets U.S. Food and Drug Administration (FDA) requirements to begin a Phase 1 clinical trial testing ADXS-NEO — a potential immunotherapy made by Advaxis to treat a…

Top 10 Alzheimer’s Disease Stories of 2018

Top 10 Alzheimer’s Disease Stories of 2018

This post was originally published on this site Throughout 2018, Alzheimer’s News Today brought you stories of important discoveries, treatment developments, clinical trials, and other events related to Alzheimer’s disease. As we look forward to providing more news to those living with Alzheimer’s as well as their family members and caregivers this year, here are the 10…

African-Americans with Alzheimer’s Have Lower Expression of 2 Common Biomarkers, Study Finds

African-Americans with Alzheimer’s Have Lower Expression of 2 Common Biomarkers, Study Finds

This post was originally published on this site African-Americans have lower expression of two biomarkers of Alzheimer’s, suggesting a possible race-dependent biological mechanism that contributes to the development of the disease, a study shows. This discrepancy between African-American and white patients is particularly relevant for those who carry the ApoE4 variant of the ApoE gene. The study,…

Alzheimer’s Association Funds 2-Year Extension of Study that Explores Intensive Blood Pressure Treatment on Dementia Risk

Alzheimer’s Association Funds 2-Year Extension of Study that Explores Intensive Blood Pressure Treatment on Dementia Risk

This post was originally published on this site The Alzheimer’s Association has funded a two-year extension of the SPRINT-MIND study — SPRINT MIND 2.0 — to further explore the role of intensive treatment to lower blood pressure and the risk of dementia. The funding, which totals more than $800,000, will allow researchers to follow the participants of the original…

Cervical Cancer Patient Achieves Long-lasting Response to AXAL in Clinical Trial

Cervical Cancer Patient Achieves Long-lasting Response to AXAL in Clinical Trial

This post was originally published on this site One of nine cervical cancer patients treated with AXAL achieved a long-lasting partial response to the therapy, according to a Phase 1 study. The treatment’s maker, Advaxis, presented the results in a poster session at a National Cancer Research Institute conference in Liverpool, England. The trial covered patients with persistent or…

Chemotherapy Plus P53 Gene Therapy May Help Treat Locally Advanced Cervical Cancer

Chemotherapy Plus P53 Gene Therapy May Help Treat Locally Advanced Cervical Cancer

This post was originally published on this site Locally advanced cervical cancer (LACC) may be treated with a combination of neoadjuvant chemotherapy (administered before surgery) and p53 gene therapy, according to a new clinical trial. The trial results, titled “Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial,”…

New Study to Assess ADXS-DUAL, Opdivo Immunotherapy Combo in Metastatic Cervical Cancer

New Study to Assess ADXS-DUAL, Opdivo Immunotherapy Combo in Metastatic Cervical Cancer

This post was originally published on this site Advaxis and Bristol-Myers Squibb have entered a clinical collaboration to evaluate the second generation of axalimogene filolisbac, called ADXS-DUAL, in combination with Opdivo (nivolumab) in women with metastatic cervical cancer. In particular, the study will assess the combination in patients with persistent, recurrent or metastatic (squamous or…